| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 39.66 | 9.5% | 53.3% |
| Total Income | 39.66 | 9.5% | 53.3% |
| Expenditure | 21.05 | 16.4% | 13.1% |
| PBT | 12.79 | 71.5% | 83.4% |
| Net Profit | 8.75 | 76.9% | 88.3% |
| OPM | 42.30% | 57.70pp | |
| NPM | 22.07% | 77.93pp | 77.93pp |
| EPS | 0.14 | 77.4% | 88.7% |
Zevra Therapeutics Reports Q2 2026 Financial Results and Corporate Update
06 Aug 2026 · 6 Aug, 1:52 am
Summary
Zevra Therapeutics announced its financial results for the second quarter ended June 30, 2026, reporting $39.7 million in net revenue, a 53% increase year-over-year, largely driven by $30.2 million in revenue from MIPLYFFA. The company ended the quarter with a strong cash position of $260.2 million, which it believes is sufficient to execute its strategic priorities. While net income was $8.8 million ($0.14 per diluted share) in Q2 2026, this compares to a significantly higher $74.7 million ($1.21 per diluted share) in Q2 2025, which included a one-time gain on the sale of a priority review voucher. Management highlighted strong MIPLYFFA performance and U.S. commercial execution, while also pursuing European access for arimoclomol and advancing its celiprolol trial for VEDS.
Key Highlights
- 1
Zevra Therapeutics reported $39.7 million in net revenue for the second quarter of 2026, an increase of 53% over the same period in 2025.
- 2
Revenue for Q2 2026 was driven by $30.2 million in revenue from MIPLYFFA.
- 3
The company maintained a strong cash position of $260.2 million as of June 30, 2026.
- 4
Net income for Q2 2026 was $8.8 million, or $0.14 per diluted share, compared to a net income of $74.7 million, or $1.21 per diluted share, in Q2 2025.
- 5
Operating expenses decreased to $21.0 million in Q2 2026 from $24.2 million in Q2 2025.
- 6
The Phase 3 DiSCOVER trial of celiprolol for Vascular Ehlers-Danlos Syndrome enrolled four patients in Q2 2026, bringing the total to 66.
Management Comments
Neil F. McFarlane
Zevra delivered strong MIPLYFFA performance and further established the therapy as an important treatment option for people living with Niemann-Pick disease type C. These results reflect the strength of our U.S. commercial execution. Additionally, we are pursuing access to arimoclomol for people living with NPC in Europe, and we have submitted a request for the re-examination of our Marketing Authorisation Application. Our global Expanded Access Program remains active for eligible patients, reflecting our steadfast commitment to patients and families.
Informational and educational content only. Not investment advice.